|
COPYRIGHT 2004 International Medical News Group
CAMBRIDGE, MD. -- The few interventions that have shown some effectiveness in helping patients with nonalcoholic fatty liver disease have not accumulated enough evidence to recommend their use, Steven F. Solga, M.D., said at a hepatobiliary update sponsored by Johns Hopkins University.
Effective treatments for nonalcoholic fatty liver disease (NAFLD) are necessary because patients with compensated cirrhosis have a similar risk of death regardless of whether they have an etiology of nonalcoholic steatohepatitis (NASH) or other liver diseases.
NASH is the severest form of liver disease on the spectrum of NAFLD, which begins with simple steatosis and steatosis with inflammation.
Patients with NASH who are "destined to develop cirrhosis"--usually defined as those who have increased fibrosis on liver biopsy, an age of at least 45-50 years, obesity, or diabetes--need...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
